Dermira Inc (NASDAQ:DERM) has been assigned an average rating of “Hold” from the ten brokerages that are presently covering the company, Marketbeat reports. Three investment analysts have rated the stock with a sell rating and seven have issued a buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $41.00.
Several equities analysts recently commented on the stock. Leerink Swann reiterated an “outperform” rating and set a $41.00 price target (down from $47.00) on shares of Dermira in a report on Tuesday, November 7th. Guggenheim began coverage on shares of Dermira in a research note on Tuesday, December 5th. They issued a “buy” rating on the stock. Mizuho dropped their target price on shares of Dermira from $43.00 to $39.00 and set a “buy” rating on the stock in a research note on Tuesday, December 12th. Needham & Company LLC restated a “buy” rating and issued a $43.00 target price (down from $46.00) on shares of Dermira in a research note on Tuesday, November 7th. Finally, BidaskClub upgraded shares of Dermira from a “hold” rating to a “buy” rating in a research note on Wednesday, December 20th.
In related news, SVP Christopher M. Griffith sold 18,458 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $27.05, for a total transaction of $499,288.90. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Eugene A. Bauer sold 3,000 shares of the stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $27.34, for a total transaction of $82,020.00. The disclosure for this sale can be found here. Insiders sold a total of 48,758 shares of company stock valued at $1,348,773 in the last ninety days. Corporate insiders own 13.30% of the company’s stock.
Dermira (NASDAQ:DERM) opened at $27.35 on Monday. The company has a market cap of $1,139.79, a PE ratio of -4.39 and a beta of 0.80. Dermira has a fifty-two week low of $21.35 and a fifty-two week high of $38.75. The company has a current ratio of 4.68, a quick ratio of 4.68 and a debt-to-equity ratio of 1.40.
ILLEGAL ACTIVITY WARNING: “Dermira Inc (DERM) Receives Average Recommendation of “Hold” from Brokerages” was published by BBNS and is owned by of BBNS. If you are accessing this piece of content on another domain, it was stolen and reposted in violation of international copyright & trademark laws. The correct version of this piece of content can be accessed at https://baseballnewssource.com/markets/dermira-inc-derm-receives-average-recommendation-of-hold-from-brokerages/1817467.html.
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.